Development of a cyclin-dependent kinase inhibitor devoid of ABC transporter-dependent drug resistance

摘要

Background:Cyclin-dependent kinases (CDKs) control cell cycle progression, RNA transcription and apoptosis, making them attractive targets for anticancer drug development. Unfortunately, CDK inhibitors developed to date have demonstrated variable efficacy.